Neng-Yao Shih received his Ph.D. (1996) in molecular and cell biology from the Arizona State University, and followed by a post-doctoral training in the Medical School of Washington University in St. Louis (1997-2000), studying the role of CD2-associated protein in T cell activation. In 2001, he started to develop his scientific career in the National Health Research Institutes, where he is a pioneer on identification of immunogenic tumor-associated antigens (TAAs) from lung cancer patients. In his previous studies, he demonstrated that immune-targeting to those TAAs could significantly provide a better survival benefit on cancer prevention and therapy. Neng-Yao Shih received his Ph.D. (1996) in molecular and cell biology from the Arizona State University, and followed by a post-doctoral training in the Medical School of Washington University in St. Louis (1997-2000), studying the role of CD2-associated protein in T cell activation. In 2001, he started to develop his scientific career in the National Health Research Institutes, where he is a pioneer on identification of immunogenic tumor-associated antigens (TAAs) from lung cancer patients. In his previous studies, he demonstrated that immune-targeting to those TAAs could significantly provide a better survival benefit on cancer prevention and therapy.

vaccine, Immunology